AstraZeneca Biopharma Spinout Entasis Files for IPO
August 17 2018 - 8:18PM
Dow Jones News
By Josh Beckerman
Entasis Therapeutics Holdings Inc., a developer of antibiotics
that spun out from AstraZeneca PLC (AZN, AZN.LN) in 2015, has
revealed its plans for an initial public offering.
Entasis, which previously filed confidential IPO paperwork, said
in its Form S-1 Friday it has applied to list on Nasdaq under
symbol ETTX.
The Waltham, Mass., biopharmaceutical company filed to offer up
to $86.25 million, but that is a placeholder amount likely to
change.
AstraZeneca owns a 21.6% stake in Entasis. Other large
shareholders include Clarus Ventures, which owns 14.7%.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 17, 2018 20:03 ET (00:03 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
